SAN DIEGO, Oct. 25, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 622,500 shares of common stock at a public offering price of $7.25 per share,......
More...